This nuclear receptor assay system utilizes proprietary non-human cells engineered to provide constitutive, high-level expression of the human retinoic acid receptor gamma (NR1B3), a ligand-dependent transcription factor commonly referred to as RARG or RARγ. The reporter cells include the luciferase reporter gene functionally linked to a RARγ-responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in RARγ activity. The principal application of this reporter assay system is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human RARγ. RARγ reporter cells are prepared using the proprietary CryoMite process. This cryo-preservation method yields exceptional cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spin-and-rinse of cells, viability determinations, cell titer adjustments, or the preincubation of reporter cells prior to assay setup. The nuclear receptor reporter assays are all-inclusive cell-based assay systems. In addition to RARγ reporter cells, this kit provides two optimized media for use during cell culture and in diluting the user"s test samples, a reference agonist, luciferase detection reagent, and a cell culture-ready assay plate.
▪ RARγ Reporter Cells: 3 x 0.60 mL; -80°C▪ Cell Recovery Medium (CRM): 1 x 10.5 mL; -20°C▪ Compound Screening Medium (CSM): 1 x 35 mL; -20°C ▪ trans-Retinoic Acid, 10 mM (in DMSO) (reference agonist for RARγ): 1 x 30 µL; -20°C▪ Detection Substrate: 3 x 2.0 mL; -80°C ▪ Detection Buffer: 3 x 2.0 mL; -80°C▪ Plate frame: 1; ambient ▪ Snap-in, 8-well strips: 12; ambient